Beverly Moy (@beverlymoy) 's Twitter Profile
Beverly Moy

@beverlymoy

Medical Oncologist, Director of Cancer Equity & Clinical Director of Breast Oncology at Mass General Hospital; Professor, Harvard Medical School. Views my own.

ID: 1463076127

calendar_today27-05-2013 20:19:42

495 Tweet

1,1K Takipçi

288 Takip Edilen

ASCO (@asco) 's Twitter Profile Photo

Just issued: Rapid guideline update on endocrine and targeted therapy for HR-positive, HER2-negative metastatic #BreastCancer - capivasertib-fulvestrant. Read more: brnw.ch/21wHQVC #bcsm #mBC

Just issued: Rapid guideline update on endocrine and targeted therapy for HR-positive, HER2-negative metastatic #BreastCancer - capivasertib-fulvestrant. Read more: brnw.ch/21wHQVC #bcsm #mBC
Beverly Moy (@beverlymoy) 's Twitter Profile Photo

I am in awe of Mass General Cancer Center MGH Women in Oncology Aparna Raj Parikh running her first marathon to raise funds for ColinsJoyProject to enhance children/family program in S Boston. The McGrath family inspires us all boston.com/community/bost…

Rick Lee 이재방 (@ricklee6) 's Twitter Profile Photo

I’m pleased to help organize with James ‘Jimmy’ Hills the THIRD Your Healthy Java / Joseph R Betancourt Health Fair in Roxbury, Boston, MA. We are bringing cancer specialists and information to the community on Saturday, May 11, 2024. Please join us!

I’m pleased to help organize with <a href="/javawithJimmy/">James ‘Jimmy’ Hills</a> the THIRD Your Healthy Java / Joseph R Betancourt Health Fair in Roxbury, Boston, MA. We are bringing cancer specialists and information to the community on Saturday, May 11, 2024. Please join us!
James ‘Jimmy’ Hills (@javawithjimmy) 's Twitter Profile Photo

Saturday’s #YourHealthyJava Joseph R. Betancourt Health Fair is made possible J&J Innovative Medicine & Bayer U.S. 🇺🇸 & The New Commonwealth Fund Thank you to our sponsors. Join us... jwj.info/healthfair24! Also thanks to Rick Lee 이재방 for picking up the mantle from Joseph Betancourt supporting #healthequity

Saturday’s #YourHealthyJava Joseph R. Betancourt Health Fair is made possible <a href="/JNJInnovMed/">J&J Innovative Medicine</a> &amp; <a href="/BayerUS/">Bayer U.S. 🇺🇸</a> &amp; <a href="/NCFMass/">The New Commonwealth Fund</a> 

Thank you to our sponsors.

Join us... jwj.info/healthfair24! 

Also thanks to <a href="/RickLee6/">Rick Lee 이재방</a> for picking up the mantle from <a href="/Jbetancourtpr/">Joseph Betancourt</a> supporting #healthequity
Beverly Moy (@beverlymoy) 's Twitter Profile Photo

Amazing to celebrate the brilliant Conquer Cancer Foundation grant awardees, especially proud of ⁦⁦Rachel Occhiogrosso Abelman, MD⁩ Ellis, Leon Pappas YIA winners and Catherine Meador CDA winner of ⁦Mass General Cancer Center⁩ #ASCO24

Amazing to celebrate the brilliant Conquer Cancer Foundation grant awardees, especially proud of ⁦⁦<a href="/RachelAbelman/">Rachel Occhiogrosso Abelman, MD</a>⁩ Ellis, Leon Pappas YIA winners and Catherine Meador CDA winner of ⁦<a href="/MGHCancerCenter/">Mass General Cancer Center</a>⁩ #ASCO24
Beverly Moy (@beverlymoy) 's Twitter Profile Photo

Goals of care conversations should happen early and throughout the disease trajectory. ⁦Mass General Cancer Center⁩ ⁦MGH Women in Oncology⁩ ⁦MGH Breast Oncology⁩ Dr. Jenn Shin takes us through how to respond, understand, respect, support, and explore in these conversations.

Goals of care conversations should happen early and throughout the disease trajectory. ⁦<a href="/MGHCancerCenter/">Mass General Cancer Center</a>⁩ ⁦<a href="/MGH_WiO/">MGH Women in Oncology</a>⁩ ⁦<a href="/MGHBreastOnc/">MGH Breast Oncology</a>⁩ Dr. Jenn Shin takes us through how to respond, understand, respect, support, and explore in these conversations.
Beverly Moy (@beverlymoy) 's Twitter Profile Photo

Kevin Kalinsky, MD, MS, FASCO⁩ presents postMONARCH, the first trial showing benefit of continuing CDK4/6 inhibition after progression on prior CDK. Congrats to investigators, including senior author ⁦Mass General Cancer Center⁩ ⁦MGH Breast Oncology⁩ Seth Wander #ASCO24

⁦<a href="/KalinskyKevin/">Kevin Kalinsky, MD, MS, FASCO</a>⁩ presents postMONARCH, the first trial showing benefit of continuing CDK4/6 inhibition after progression on prior CDK. Congrats to investigators, including senior author ⁦<a href="/MGHCancerCenter/">Mass General Cancer Center</a>⁩ ⁦<a href="/MGHBreastOnc/">MGH Breast Oncology</a>⁩ Seth Wander #ASCO24
Beverly Moy (@beverlymoy) 's Twitter Profile Photo

Triple combo of inavolisib plus palbo plus fulvestrant meaningfully improves PFS and more in first line met ER+ PIK3CA mutant breast cancer. This is a very promising treatment. Amazing work energetically presented by ⁦Mass General Cancer Center⁩ Dejan Juric and colleagues #ASCO24

Triple combo of inavolisib plus palbo plus fulvestrant meaningfully improves PFS and more in first line met ER+ PIK3CA mutant breast cancer. This is a very promising treatment. Amazing work energetically presented by ⁦<a href="/MGHCancerCenter/">Mass General Cancer Center</a>⁩ Dejan Juric and colleagues #ASCO24
Beverly Moy (@beverlymoy) 's Twitter Profile Photo

Amazing discussion with Lori Pierce and ⁦Dr. Rob Winn⁩ at #ASCO24 EDI breakfast. “We have to do what is possible.” How we respond to challenges is vital. Missing 3 giants: Worta McCaskill-Stevens, Bill Blackstock, and Edith Mitchell.

Amazing discussion with Lori Pierce and ⁦<a href="/DrRobWinn/">Dr. Rob Winn</a>⁩ at #ASCO24 EDI breakfast. “We have to do what is possible.” How we respond to challenges is vital. Missing 3 giants: Worta McCaskill-Stevens, Bill Blackstock, and Edith Mitchell.
Beverly Moy (@beverlymoy) 's Twitter Profile Photo

I’m honored and thrilled to chair the brilliant ⁦ASCO⁩ Evidence Based Medicine Committee charged to provide the highest quality clinical practice #ASCOGuidelines. An impressive group of volunteer experts and staff! Lotsa guidelines coming your way!

I’m honored and thrilled to chair the brilliant ⁦<a href="/ASCO/">ASCO</a>⁩ Evidence Based Medicine Committee charged to provide the highest quality clinical practice #ASCOGuidelines. An impressive group of volunteer experts and staff! Lotsa guidelines coming your way!
ASCO (@asco) 's Twitter Profile Photo

We’ve issued a rapid guideline update for the management of stage III #NSCLC. ➡️ brnw.ch/21wKCWv #lungcancer #lcsm

We’ve issued a rapid guideline update for the management of stage III #NSCLC. ➡️ brnw.ch/21wKCWv #lungcancer #lcsm
ASCO (@asco) 's Twitter Profile Photo

We’ve issued a rapid guideline update on systemic therapy for #sclc. These recommendations are considered provisional pending full text review of publication and confirmation of data. ➡️ brnw.ch/21wKD3i #lungcancer #lcsm

We’ve issued a rapid guideline update on systemic therapy for #sclc. These recommendations are considered provisional pending full text review of publication and confirmation of data. ➡️ brnw.ch/21wKD3i #lungcancer #lcsm
Matthew Gubens (@mattgubensmd) 's Twitter Profile Photo

Such warm hospitality from Indonesian oncologists! Representing #ASCOGuidelines @asco at their annual oncology meeting, ISMI HOTTI. Jakarta is the kota kolaborasi, or city of collaboration, indeed! Thanks Beverly Moy Christina Annunziata Nancy Baxter MD PhD for joining virtually! Thanks for having

Such warm hospitality from Indonesian oncologists! Representing #ASCOGuidelines @asco at their annual oncology meeting, ISMI HOTTI. Jakarta is the kota kolaborasi, or city of collaboration, indeed! Thanks <a href="/BeverlyMoy/">Beverly Moy</a> <a href="/CMAnnunziata/">Christina Annunziata</a> <a href="/enenbee/">Nancy Baxter MD PhD</a> for joining virtually! Thanks for having
Beverly Moy (@beverlymoy) 's Twitter Profile Photo

I am thrilled to support Mass General Cancer Center MGH Women in Oncology team! Please donate or join us on Sep 15th to see if the rumors that I am singing with Jeffrey peppercorn MD band "What She Said" are true. because.massgeneral.org/fundraiser/572…

Beverly Moy (@beverlymoy) 's Twitter Profile Photo

The US FDA has approved adjuvant ribociclib + AI for HR+ HER2- Stage II and III breast cancer pts. Let's put our heads together to better explore appropriate use, given pt financial burden, ~8% grade 3 transaminase rate, and other toxicity. Choice of CDK 4/6 inhibitor? Duration?